French National Database of Rare Dermatological Cancers

Study Purpose

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are :

  • - to provide epidemiological, clinical and socio-economic characteristics of patients.
  • - to identify new clinical or epidemiological prognostic factors for these rare cancers.
- to evaluate the impact of various treatments on outcomes

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages N/A and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma.

Exclusion Criteria:

  • - Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma.
- Patients refusal

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03210935
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University Hospital, Lille
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Laurent MORTIER, MD,PhD
Principal Investigator Affiliation University Hospital, Lille
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Adnexal Tumor of Skin, Merkel Cell Carcinoma, Advanced Basal Cell Carcinoma Requiring Systemic Treatment
Study Website: View Trial Website
Additional Details

CARADERM is a French national multidisciplinary project which will prospectively enroll from 37 French centers any patient presenting with Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment or cutaneous adnexal carcinoma. A structured and centralized database of clinical monitoring of patients will be established. Information captured will include clinical constitutional factors, factors linked to primary carcinoma, factors linked to lymph node involvement, "American Joint Committee on Cancer" (AJCC) stage at inclusion, recurrence patterns, therapeutic interventions (medical, surgical, radiotherapy and palliative strategies) with evaluation of response, date of death, date of latest news.

Arms & Interventions

Arms

: Merkel cell carcinoma

: Advanced basal cell carcinoma

: Cutaneous adnexal carcinomas

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

CHU Amiens Picardie, Amiens, France

Status

Recruiting

Address

CHU Amiens Picardie

Amiens, ,

Site Contact

Catherine Lok, MD

[email protected]

03.20.44.41.93

CHU Angers, Angers, France

Status

Recruiting

Address

CHU Angers

Angers, ,

Site Contact

Ludovic Martin, MD

[email protected]

03.20.44.41.93

CH Annecy Gennevois, Annecy, France

Status

Recruiting

Address

CH Annecy Gennevois

Annecy, ,

Site Contact

Julie De Quatrebarbes, MD

[email protected]

03.20.44.41.93

CHU Besançon, Besançon, France

Status

Recruiting

Address

CHU Besançon

Besançon, ,

Site Contact

François Aubin, MD

[email protected]

03.20.44.41.93

CHU Avicenne, Bobigny, France

Status

Recruiting

Address

CHU Avicenne

Bobigny, ,

Site Contact

Eve Maubec, MD

[email protected]

03.20.44.41.93

CHU Ambroise Paré, Boulogne-Billancourt, France

Status

Recruiting

Address

CHU Ambroise Paré

Boulogne-Billancourt, ,

Site Contact

Philippe Saiag, MD

[email protected]

03.20.44.41.93

CHU de Brest, Brest, France

Status

Recruiting

Address

CHU de Brest

Brest, ,

Site Contact

Laurent Misery, MD

[email protected]

03.20.44.41.93

CHU de Caen, Caen, France

Status

Recruiting

Address

CHU de Caen

Caen, ,

Site Contact

Laurence VERNEUIL, MD, PhD

[email protected]

03.20.44.41.93

CHU de Clermont Ferrand, Clermont Ferrand, France

Status

Recruiting

Address

CHU de Clermont Ferrand

Clermont Ferrand, ,

Site Contact

Michel d'Incan, MD

[email protected]

03.20.44.41.93

CHU Bocage, Dijon, France

Status

Recruiting

Address

CHU Bocage

Dijon, , 21079

Site Contact

sophie DALAC, md

[email protected]

03 80 29 33 36

CHU de Grenoble, Grenoble, France

Status

Recruiting

Address

CHU de Grenoble

Grenoble, ,

Site Contact

Marie-Therese Leccia, MD

[email protected]

03.20.44.41.93

CH Le Mans, Le Mans, France

Status

Recruiting

Address

CH Le Mans

Le Mans, , 72037

Site Contact

Nathalie BENETON-BENHARD, md

[email protected]

02 43 43 43 58

CHU de Limoges, Limoges, France

Status

Recruiting

Address

CHU de Limoges

Limoges, ,

Site Contact

Christophe Bedane, MD

[email protected]

03.20.44.41.93

Centre Léon Bérard, Lyon, France

Status

Recruiting

Address

Centre Léon Bérard

Lyon, ,

Site Contact

Patrick Combemasle, MD

[email protected]

03.20.44.41.93

Hôpital La Timone, Marseille, France

Status

Recruiting

Address

Hôpital La Timone

Marseille, ,

Site Contact

Jean Jacques Grob, MD

[email protected]

03.20.44.41.93

Hôpital St Eloi, Montpellier, France

Status

Recruiting

Address

Hôpital St Eloi

Montpellier, ,

Site Contact

Bernard Guillot, MD

[email protected]

03.20.44.41.93

CHU de Nancy, Nancy, France

Status

Recruiting

Address

CHU de Nancy

Nancy, ,

Site Contact

Florence Granel-Brocard, MD

[email protected]

03.20.44.41.93

CHU Nantes - Place Alexis Ricordeau, Nantes, France

Status

Recruiting

Address

CHU Nantes - Place Alexis Ricordeau

Nantes, ,

Site Contact

Brigitte DRENO, MD, PhD

[email protected]

03.20.44.41.93

CHU de Nice, Nice, France

Status

Recruiting

Address

CHU de Nice

Nice, ,

Site Contact

Jean Philippe Lacour, MD

[email protected]

03.20.44.41.93

CHR d'Orleans, Orléans, France

Status

Recruiting

Address

CHR d'Orleans

Orléans, ,

Site Contact

Guido Bens, MD

[email protected]

03.20.44.41.93

CHU Bichat, Paris, France

Status

Recruiting

Address

CHU Bichat

Paris, ,

Site Contact

Vincent Descamps, MD

[email protected]

03.20.44.41.93

CHU Cochin, Paris, France

Status

Recruiting

Address

CHU Cochin

Paris, ,

Site Contact

Selim Aractingi, MD

[email protected]

03.20.44.41.93

CHU St Louis, Paris, France

Status

Recruiting

Address

CHU St Louis

Paris, ,

Site Contact

Celeste Lebbe, MD

[email protected]

03.20.44.41.93

CHU de Bordeaux, Pessac, France

Status

Recruiting

Address

CHU de Bordeaux

Pessac, ,

Site Contact

Marie BEYLOT-BARRY, MD, PhD

[email protected]

03.20.44.41.93

Centre hospitalier Lyon Sud, Pierre-benite, France

Status

Recruiting

Address

Centre hospitalier Lyon Sud

Pierre-benite, , 69495

Site Contact

luc THOMAS, md,phd

[email protected]

04 78 86 16 79

CHU de Pointe à Pitre, Pointe À Pitre, France

Status

Recruiting

Address

CHU de Pointe à Pitre

Pointe À Pitre, ,

Site Contact

Nadège Cordel, MD

[email protected]

03.20.44.41.93

CHU de Poitiers, Poitiers, France

Status

Recruiting

Address

CHU de Poitiers

Poitiers, ,

Site Contact

Gerard Guillet, MD

[email protected]

03.20.44.41.93

CHU de Reims, Reims, France

Status

Recruiting

Address

CHU de Reims

Reims, ,

Site Contact

Florent Grange, MD

[email protected]

03.20.44.41.93

CHU de Rennes, Rennes, France

Status

Recruiting

Address

CHU de Rennes

Rennes, ,

Site Contact

Alain Dupuy

[email protected]

03.20.44.41.93

CHU de Rouen, Rouen, France

Status

Recruiting

Address

CHU de Rouen

Rouen, ,

Site Contact

Pascal JOLY, MD, PhD

[email protected]

03.20.44.41.93

CHU de Strasbourg, Strasbourg, France

Status

Recruiting

Address

CHU de Strasbourg

Strasbourg, ,

Site Contact

Dan Lipsker, MD

[email protected]

03.20.44.41.93

CHU de Toulouse - Larrey, Toulouse, France

Status

Recruiting

Address

CHU de Toulouse - Larrey

Toulouse, ,

Site Contact

Nicolas MEYER, MD, PhD

[email protected]

03.20.44.41.93

CHU de Tours, Tours, France

Status

Recruiting

Address

CHU de Tours

Tours, ,

Site Contact

Laurent Machet, MD

[email protected]

03.20.44.41.93

Institut Gustave Roussy, Villejuif, France

Status

Recruiting

Address

Institut Gustave Roussy

Villejuif, ,

Site Contact

Caroline ROBERT, MD, PhD

[email protected]

03.20.44.41.93

Stay Informed & Connected